Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi ...

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

Long-term data on four patients' who had received avigbagene parvec gave the firm confidence to advance a late-stage single-arm trial that can support regulatory approval.

GT Biopharma is set to begin a Phase I trial in mid-2026 of its B7-H3-targeting natural killer cell engager, after the US Food and Drug Administration cleared its investigational new drug application ...

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle ...

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective ...

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a ...